Hsbc Holdings Plc acquired 863,733 shares as Amgen Inc (AMGN)'s stock declined 9.68%. Its share price has risen 3.88% in three months and is up 1.16% for the last five trades. Amgen has a one year low of $133.64 and a one year high of $176.85.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Monday, October 9th. About shares traded. Amgen, Inc. (NASDAQ:AMGN) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. It has underperformed by 11.43% the S&P500. Eagle Asset Mgmt holds 2.49 million shares. The company has market cap of $336.43 million. (NASDAQ:AMGN) news were published by: Finance.Yahoo.com which released: "What's in the Cards for Amgen (AMGN) this Earnings Season?" on October 20, 2017, also Nasdaq.com with their article: "Trust Co Of Toledo Na Buys Exelon Corp, Amgen Inc, Omnicom Group Inc, Sells EI ..." published on October 11, 2017, Fool.com published: "Amgen Wins Reprieve on Its 2nd-Best-Selling Drug" on October 10, 2017. Altria Group Inc (NYSE:MO) has risen 11.92% since October 23, 2016 and is uptrending. It has outperformed by 77.74% the S&P500. Swiss National Bank raised its holdings in Amgen by 26.5% in the 1st quarter. (NASDAQ:AMGN) for 88,293 shares.
More notable recent Amgen, Inc. Tocqueville Asset Lp owns 0.18% invested in Amgen, Inc.
Investors sentiment decreased to 1.15 in 2017 Q2. Its down 0.01, from 1.15 in 2017Q1. It dropped, as 72 investors sold AMGN shares while 463 reduced holdings. Penserra Capital Management LLC boosted its stake in Amgen by 100.0% in the third quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company's stock worth $293,869,000 after purchasing an additional 676,300 shares during the period. Scotia Capital holds 0.06% of its portfolio in Amgen, Inc. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16.
TRADEMARK VIOLATION NOTICE: "First Trust Advisors LP Buys 80,852 Shares of Amgen Inc". During the past six months, Amgen Inc. (NASDAQ:AMGN). Axa reported 974,085 shares or 0.76% of all its holdings. Highvista Strategies Limited Liability Company holds 0.68% or 53,700 shares in its portfolio. (NASDAQ:AMGN). Investment Partners Limited Oh Adv holds 0.34% or 2,192 shares in its portfolio. 4,795 were reported by One Trading L P. Peapack Gladstone Corporation has 66,508 shares for 0% of their portfolio. Moreover, Sadoff Invest Lc has 0.08% invested in Altria Group Inc (NYSE:MO). (NASDAQ:AMGN). 2,003 are owned by Beech Hill Advisors. Zwj Invest Counsel invested in 0.09% or 6,653 shares. Calamos Wealth Mngmt Ltd Liability has invested 0.23% in Amgen, Inc. 251,554 were reported by Toronto Dominion Bank & Trust. Joel Isaacson Ltd Liability, New York-based fund reported 2,978 shares. Highlander Cap Mgmt Limited Liability Corp owns 2,200 shares or 0.3% of their United States portfolio. BALTIMORE DAVID also sold $569,541 worth of Amgen, Inc.
Analysts await BioSpecifics Technologies Corp. (NASDAQ:AMGN) has "Overweight" rating given on Thursday, November 5 by Piper Jaffray. They expect $3.07 earnings per share, up 1.66% or $0.05 from last year's $3.02 per share. Asset Advsrs reported 1.06% in Amgen, Inc. On average, equities research analysts anticipate that Amgen Inc. will post $12.58 EPS for the current fiscal year. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 11 Hold. Therefore 50% are positive. Amgen Inc. had 67 analyst reports since August 3, 2015 according to SRatingsIntel. Finally, Argus upped their price target on shares of Amgen from $180.00 to $195.00 and gave the company a "buy" rating in a report on Thursday, July 27th. Groesbeck Inv Corporation Nj stated it has 3.28% in Amgen, Inc.
Among 16 analysts covering InterActiveCorp (NASDAQ:IAC), 13 have Buy rating, 0 Sell and 3 Hold. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 11 Hold. Credit Suisse initiated the shares of AMGN in report on Wednesday, January 20 with "Outperform" rating. Oppenheimer maintained Amgen, Inc. (NASDAQ:AMGN) earned "Overweight" rating by Morgan Stanley on Friday, October 6. The firm has "Outperform" rating given on Friday, July 31 by RBC Capital Markets. The firm has "Neutral" rating by Citigroup given on Thursday, February 25. (NASDAQ:AMGN) has "Buy" rating given on Friday, July 21 by Oppenheimer. Raymond James initiated the shares of AMGN in report on Tuesday, September 1 with "Market Perform" rating. Cann reaffirmed a "buy" rating and issued a $203.00 price target (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Camelot Portfolios LLC acquired a new stake in Amgen in the first quarter valued at $1,429,000. The company's quarterly revenue was up 2.1% on a year-over-year basis.
Investors sentiment decreased to 1.15 in Q2 2017. Its down 0.05, from 1.34 in 2017Q1. 97 funds opened positions while 444 raised stakes. 124.48 million shares or 4.08% more from 119.60 million shares in 2017Q1 were reported. 44,046 were accumulated by Bowling Portfolio Management Ltd. Dnb Asset Management As reported 0% in Expedia Inc (NASDAQ:EXPE). The California-based Rice Hall James & Associates Llc has invested 0.35% in the stock. Haverford Trust Company accumulated 0.24% or 62,746 shares. Fukoku Mutual Life Insurance Com invested in 2,100 shares. The company has a market cap of $133.50 billion, a P/E ratio of 16.66 and a beta of 1.36.
Investors are always on the look for the next great stock to own. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company's stock worth $446,250,000 after purchasing an additional 81,362 shares during the period. Alphamark Advisors Limited holds 2.27% of its portfolio in Amgen, Inc.
Capital International Sarl decreased International Business Machines Corp (NYSE:IBM) stake by 5,300 shares to 3,000 valued at $461,000 in 2017Q2. About 4.10M shares traded.
Analysts await Expedia Inc (NASDAQ:EXPE) to report earnings on October, 26. IAC's profit would be $56.64 million giving it 43.92 P/E if the $0.71 EPS is correct. After $0.36 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.